Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy

SHANGHAI, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON® indicated “to reduce the…

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

Luxembourg, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE")…

CITIC Telecom CPC Propels ‘+AI to AI+’

HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is at the forefront of AI+ innovation era, enabling dual empowerment of technology and data, and fostering a new business model…

China Medical System: First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

SHENZHEN, CHINA, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the…

Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells

ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activitiesNo serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification…

GTJAI Signed the Good Employer Charter Again

HONG KONG, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - Guotai Junan International Holdings Limited (“Guotai Junan International”, “GTJAI”, the “Company” or the “Group”, stock code: 1788.HK) is pleased to announce that the Company has participated in the Good Employer Charter Scheme launched by the Hong Kong Labour Department…

Graphene Manufacturing Group (GMG) Provides Commercialisation Update on Energy Savings Coating THERMAL-XR(R)

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - October 16, 2024) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to provide a business update on the commercialisation progress of THERMAL-XR® Powered by GMG Graphene.CUSTOMER ENGAGEMENT UPDATEGMG continues to carry out both Supply and Service Coating for…

HKTDC welcomes 2024 Policy Address

HONG KONG, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) welcomes the 2024 Policy Address, delivered today by the Hong Kong Special Administrative Region’s (HKSAR) Chief Executive John Lee.The Policy Address presents a comprehensive set of measures, ranging from the economy and trade…

Kincora Announces Strategic Investment & Expanded Partnership with Fleet Space

Kincora to raise A$1.27 million (C$1.19 million) via strategic investment by Fleet Space, existing major shareholder, directors and new investors participationRaise conducted at A$0.038 (C$0.036) with 1:2 attaching option at A$0.075 (C$0.07)Fleet Space to invest A$400,000 (C$373,832) to take initial ~4% strategic stake in KincoraExpanded partnership with Fleet Space including…